Adult Diabetes Care
About Joslin's Adult Diabetes Care Services
If diabetes is part of your life, the place to turn is Joslin Clinic. Nowhere else in the world will you find more people and programs specializing exclusively in treating all types of diabetes.
The Pathway to Lifelong Health
Joslin Clinic is the world’s first and most respected diabetes care facility. It was founded on the belief that the key to managing diabetes is with patient involvement, education and empowerment.
JoslinCareJoslinCare is a multi-disciplinary program that helps people with diabetes get state-of-the-art medical care, patient education, and aggressive prevention and management of complications.
Whether you are newly diagnosed with type 1 or type 2 diabetes, or want to improve your control and prevent complications, we can help you map out a personalized diabetes care plan.
A Team of Experts
All of our physicians, diabetes educators, and specialty providers are expert in all facets of diabetes. Joslin Clinic has the highest concentration of certified diabetes educators—nurses, dietitians, exercise physiologists, nurse practitioners and mental health professionals–anywhere in the world.
Joslin Clinic also provides inpatient medical consultation at Beth Israel Deaconess Medical Center (BIDMC).
Education: The Key to Managing Your Diabetes
Good diabetes management starts with learning skills you can use to make good food choices, increase your physical activity in an appropriate way and monitor your blood glucose level.
Joslin's expert team of Certified Diabetes Educators, including nutritionists and exercise physiology, can help you learn those skills. Read More
Diabetes Education Programs
Joslin Clinic programs provide for a wide range of options for people with diabetes, including educational programs such as:
Diabetes Weight Management Programs
Losing weight is hard—but when you have diabetes, it’s even harder.
That’s why the diabetes and weight management experts at the Joslin Diabetes Center two programs—Why WAIT? and YOU-Turn—based on extensive clinical research and designed especially for people with diabetes.
Joslin Clinic Recognitions
- The American Diabetes Association for meeting the national standards for excellence in diabetes education.
- The National Committee for Quality Assurance/American Diabetes Association Diabetes Physician Recognition Program.
- The Heart/Stroke Recognition program through the National Committee for Quality Assurance and the American Heart Association/American Stroke Association for superior cardiovascular/stroke care.
Joslin Diabetes Center has been notified of a voluntary recall of all LifeScan OneTouch® Verio®IQ Blood Glucose Meters.
It is reported that at extremely high blood glucose levels of 1024 mg/dL and above, the OneTouch® Verio®IQ Meter will turn off instead of displaying the message "EXTREME HIGH GLUCOSE above 600 mg/dL" as intended. When turned back on, the meter enters the Set-Up mode and requires the user to confirm the date and time settings before being able to test again.
However, if the glucose level is still 1024 mg/dL or above when testing, the meter will shut down again. Please contact LifeScan directly at 800-717-0276 for more details and to arrange for a replacement.
If you have questions specific to your care, please contact a Joslin professional.
This recall does not affect other OneTouch meters.
FDA: Increased Risk with Incretin Mimetics
On Thursday, March 14, the Food and Drug Administration (FDA) announced that it is evaluating unpublished findings by a group of researchers suggesting that people with type 2 diabetes who take a class of drugs called incretin mimetics have an increased risk of developing pancreatitis and changes in the pancreas called pancreatic duct metaplasia which may be associated with an increased risk for developing pancreatic cancer.
Drugs in this class include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
The FDA has previously warned the public about post marketing reports of acute pancreatitis associated with the use of the incretin mimetic drugs. Please note that the FDA has not reached any new conclusions about the safety of these drugs, or whether these drugs may cause or contribute to the development of pancreatic cancer. The FDA released this statement to inform the public that it will be reviewing this information and will make further comments once it has completed its review.
We advise patients to continue to take their medications as prescribed by their health care professionals. Stopping any medications without discussing this with your health care professional may lead to a deterioration in glucose control which is not advisable. Until there is more information we recommend that health care professionals continue to follow the prescribing indications for these medications.